ClinicalTrials.gg
Enrolling by invitationNCT06262399Updated Nov 28, 2025

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

An observational study in Hereditary Angioedema, sponsored by Intellia Therapeutics. Enrolling by invitation at 7 sites in 6 countries. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Intellia Therapeutics · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies in Angioedemas, Hereditary with a site in France — 8 open to participants now, 13 under way, 11 of them phase 3. Angioedemas, Hereditary · France.

Planned enrollment
7th of 10
100 · median 194
Started
2024
with 3 others
Observational
10 of 38
1 open now
Primary completion
2040-04
later than 12 of 12 live
Registered
26th of 38
by date
Lead sponsor
3 of 38
Intellia Therapeutics

Among the 38 studies in Angioedemas, Hereditary with a site in France, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2024, is one of 10 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 26th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

8 of the 38 studies in Angioedemas, Hereditary with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Angioedemas, Hereditary with a site in France, or all of them as a file.
02

Study summary

This is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participating sites in an Intellia-sponsored clinical study of NTLA-2002.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A subject has completed or discontinued from an Intellia-sponsored or -supported treatment protocol in which a complete or partial dose of NTLA-2002 was received.
  2. A subject has provided for the LTFU study.
  3. A subject is willing to attend study visits, complete protocol-required follow-up schedule, and comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related Adverse Events (AEs); incidence of treatment-related Serious Adverse Events (SAEs); incidence of treatment-related Adverse Events of Special Interest (AESIs) defined per protocol

    Time frame: up to 15 years

Secondary outcomes

  1. To evaluate the long-term efficacy of NTLA-2002 in previously treated subjects

    Rate of Hereditary Angioedema (HAE) attacks overall and rate of HAE attacks requiring acute therapy. Total plasma kallikrein protein level.

    Time frame: up to 15 years

  2. Change from baseline in consumption of on-demand HAE medications for reported HAE attacks

    Time frame: up to 15 years

  3. Change from baseline in healthcare utilization for HAE attacks

    Time frame: up to 15 years

  4. Change from baseline in QoL parameters as measured by the MOXIE Angioedema-QoL instrument.

    Time frame: up to 5 years

  5. Change from baseline in QoL parameters as measured by the EQ-5D-5L instrument.

    Time frame: up to 5 years

  6. Change from baseline in QoL parameters as measured by the WPAI:GH instrument.

    Time frame: up to 5 years

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2040, 192 months after the start.

Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's planned 192 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
Feb 16, 2024
StartActual
Apr 12, 2024
Primary completionEst.
Apr 2040
CompletionEst.
Apr 2040
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06262399
Lead sponsor
Intellia Therapeutics
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Apr 12, 2024
Primary completion
Apr 2040 (estimated)
Completion
Apr 2040 (estimated)
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion